{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:59:35Z","timestamp":1791417575946,"version":"4.3.3"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T00:00:00Z","timestamp":1343001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myeloid malignant diseases comprise chronic (including myelodysplastic syndromes, myeloproliferative neoplasms and chronic myelomonocytic leukemia) and acute (acute myeloid leukemia) stages. They are clonal diseases arising in hematopoietic stem or progenitor cells. Mutations responsible for these diseases occur in several genes whose encoded proteins belong principally to five classes: signaling pathways proteins (e.g. CBL, FLT3, JAK2, RAS), transcription factors (e.g. CEBPA, ETV6, RUNX1), epigenetic regulators (e.g. ASXL1, DNMT3A, EZH2, IDH1, IDH2, SUZ12, TET2, UTX), tumor suppressors (e.g. TP53), and components of the spliceosome (e.g. SF3B1, SRSF2). Large-scale sequencing efforts will soon lead to the establishment of a comprehensive repertoire of these mutations, allowing for a better definition and classification of myeloid malignancies, the identification of new prognostic markers and therapeutic targets, and the development of novel therapies. Given the importance of epigenetic deregulation in myeloid diseases, the use of drugs targeting epigenetic regulators appears as a most promising therapeutic approach.<\/jats:p>","DOI":"10.1186\/1471-2407-12-304","type":"journal-article","created":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T04:14:02Z","timestamp":1343016842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["Myeloid malignancies: mutations, models and management"],"prefix":"10.1186","volume":"12","author":[{"given":"Anne","family":"Murati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Brecqueville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Joelle","family":"Mozziconacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Gelsi-Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,23]]},"reference":[{"key":"3221_CR1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2765","volume":"10","author":"J Chen","year":"2010","unstructured":"Chen J, Odenike O, Rowley JD: Leukaemogenesis: more than mutant genes. Nat Rev Cancer. 2010, 10: 23-36.","journal-title":"Nat Rev Cancer"},{"key":"3221_CR2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365: 1054-1061.","journal-title":"Lancet"},{"key":"3221_CR3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434: 1144-1148.","journal-title":"Nature"},{"key":"3221_CR4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005, 352: 1779-1790.","journal-title":"N Engl J Med"},{"key":"3221_CR5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7: 387-397.","journal-title":"Cancer Cell"},{"key":"3221_CR6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2: 561-566.","journal-title":"Nat Med"},{"key":"3221_CR7","doi-asserted-by":"crossref","first-page":"469592","DOI":"10.1155\/2012\/469592","volume":"2012","author":"AT Fathi","year":"2012","unstructured":"Fathi AT, Abdel-Wahab O: Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol. 2012, 2012: 469592-","journal-title":"Adv Hematol"},{"key":"3221_CR8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","volume":"5","author":"V Gelsi-Boyer","year":"2012","unstructured":"Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D: Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012, 5: 12-","journal-title":"J Hematol Oncol"},{"key":"3221_CR9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/asheducation-2011.1.543","volume":"1","author":"TA Graubert","year":"2011","unstructured":"Graubert TA, Walter MJ: Genetics of Myelodysplastic Syndromes: New Insights. Hematology Am Soc Hematol Educ Program. 2011, 1: 543-549.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3221_CR10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","volume":"29","author":"G Marcucci","year":"2011","unstructured":"Marcucci G, Haferlach T, Dohner H: Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011, 29: 475-486.","journal-title":"J Clin Oncol"},{"key":"3221_CR11","first-page":"173","volume":"1825","author":"T Mercher","year":"2012","unstructured":"Mercher T, Quivoron C, Couronne L, Bastard C, Vainchenker W, Bernard OA: TET2, a tumor suppressor in hematological disorders. Biochim Biophys Acta. 2012, 1825: 173-177.","journal-title":"Biochim Biophys Acta"},{"key":"3221_CR12","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood-2008-07-167056","volume":"113","author":"FX Schaub","year":"2009","unstructured":"Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC: Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009, 113: 2022-2027.","journal-title":"Blood"},{"key":"3221_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-4-36","volume":"4","author":"S Takahashi","year":"2011","unstructured":"Takahashi S: Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011, 4: 36-","journal-title":"J Hematol Oncol"},{"key":"3221_CR14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/leu.2011.92","volume":"25","author":"A Tefferi","year":"2011","unstructured":"Tefferi A: Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up?. Leukemia. 2011, 25: 1059-1063.","journal-title":"Leukemia"},{"key":"3221_CR15","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","volume":"29","author":"F Thol","year":"2011","unstructured":"Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M, Yun H, Gohring G, Schlegelberger B, Hoelzer D, Lubbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M: Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia. J Clin Oncol. 2011, 29: 2889-2896.","journal-title":"J Clin Oncol"},{"key":"3221_CR16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"118","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA: New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011, 118: 1723-1735.","journal-title":"Blood"},{"key":"3221_CR17","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1038\/bcj.2011.15","volume":"1","author":"M Brecqueville","year":"2011","unstructured":"Brecqueville M, Cervera N, Ad\u00e9laide J, Rey J, Carbuccia N, Chaffanet M, Vey N, Birnbaum D, Murati A: Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer Journal. 2011, 1: e18-","journal-title":"Blood Cancer Journal"},{"key":"3221_CR18","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F, Dupont S, Della VV, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie F, Fontenay M, Vainchenker W, Bernard OA: Mutation in TET2 in myeloid cancers. N Engl J Med. 2009, 360: 2289-2301.","journal-title":"N Engl J Med"},{"key":"3221_CR19","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","volume":"68","author":"AJ Dunbar","year":"2008","unstructured":"Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, Sekeres MA, Wang XF, McDevitt MA, Maciejewski JP: 250\u2009K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008, 68: 10349-10357.","journal-title":"Cancer Res"},{"key":"3221_CR20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, Grand FH, Cross NC: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010, 42: 722-726.","journal-title":"Nat Genet"},{"key":"3221_CR21","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","volume":"145","author":"V Gelsi-Boyer","year":"2009","unstructured":"Gelsi-Boyer V, Trouplin V, Ad\u00e9laide J, Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prebet T, Nezri M, Sainty D, Olschwang S, Xerri L, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D: Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009, 145: 788-800.","journal-title":"Br J Haematol"},{"key":"3221_CR22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","volume":"42","author":"G Nikoloski","year":"2010","unstructured":"Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, van der Heijden A, Scheele TN, Vandenberghe P: de WT, van der Reijden BA, Jansen JH: Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010, 42: 665-667.","journal-title":"Nat Genet"},{"key":"3221_CR23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012, 481: 506-510.","journal-title":"Nature"},{"key":"3221_CR24","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK: DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010, 363: 2424-2433.","journal-title":"N Engl J Med"},{"key":"3221_CR25","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1182\/blood-2011-05-356204","volume":"118","author":"M Li","year":"2011","unstructured":"Li M, Collins R, Jiao Y, Ouillette P, Bixby D, Erba H, Vogelstein B, Kinzler KW, Papadopoulos N, Malek SN: Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood. 2011, 118: 5914-5917.","journal-title":"Blood"},{"key":"3221_CR26","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009, 361: 1058-1066.","journal-title":"N Engl J Med"},{"key":"3221_CR27","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagati A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Cross JR, Green AR, Futreal PA, Stratton MR, Campbell PJ: Somatic mutation of SF3B1 in myelodysplasia with ring sideroblasts and other cancers. N Engl J Med. 2011, 365: 1384-1395.","journal-title":"N Engl J Med"},{"key":"3221_CR28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ng.349","volume":"41","author":"G Van Haaften","year":"2009","unstructured":"Van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, Butler A, Hinton J, Latimer C, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Cole J, Forbes S, Jia M, Jones D, Kok CY, Leroy C, Lin ML, McBride DJ, Maddison M, Maquire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, Pleasance E, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turner R, Turrell K, Varian J, West S, Widaa S, Wray P, Collins VP, Ichimura K, Law S, Wong J, Yuen ST, Leung SY, Tonon G, DePinho RA, Tai YT, Anderson KC, Kahnoski RJ, Massie A, Khoo SK, Teh BT, Stratton MR, Futreal PA: Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet. 2009, 41: 521-523.","journal-title":"Nat Genet"},{"key":"3221_CR29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/leu.2011.232","volume":"26","author":"V Visconte","year":"2011","unstructured":"Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, O'Keefe C, Rogers HJ, Sekeres MA, Maciejewski JP, Tiu RV: SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2011, 26: 542-545.","journal-title":"Leukemia"},{"key":"3221_CR30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/ng.788","volume":"43","author":"XJ Yan","year":"2011","unstructured":"Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, Liang WX, Mi JQ, Song HD, Li KQ, Chen Z, Chen SJ: Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011, 43: 309-315.","journal-title":"Nat Genet"},{"key":"3221_CR31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H, Nolte F, Hofmann WK, Miyawaki S, Sugano S, Haferlach C, Koeffler HP, Shih LY, Haferlach T, Chiba S, Nakauchi H, Miyano S, Ogawa S: Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011, 478: 64-69.","journal-title":"Nature"},{"key":"3221_CR32","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1038\/onc.2010.117","volume":"29","author":"Y Yamashita","year":"2010","unstructured":"Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL, Ueno T, Soda M, Hamada T, Haruta H, Takada S, Miyazaki Y, Kiyoi H, Ito E, Naoe T, Tomonaga M, Toyota M, Tajima S, Iwama A, Mano H: Array-based genomic resequencing of human leukemia. Oncogene. 2010, 29: 3723-3731.","journal-title":"Oncogene"},{"key":"3221_CR33","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","volume":"118","author":"AM Jankowska","year":"2011","unstructured":"Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP: Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A. Blood. 2011, 118: 3932-3941.","journal-title":"Blood"},{"key":"3221_CR34","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","volume":"107","author":"RL Levine","year":"2006","unstructured":"Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, Gilliland DG, Busque L: X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006, 107: 4139-4141.","journal-title":"Blood"},{"key":"3221_CR35","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","volume":"108","author":"E Lippert","year":"2006","unstructured":"Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupre N, Skoda RC, Hermouet S: The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006, 108: 1865-1867.","journal-title":"Blood"},{"key":"3221_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","volume":"151","author":"V Gelsi-Boyer","year":"2010","unstructured":"Gelsi-Boyer V, Trouplin V, Roquain J, Ad\u00e9laide J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D: ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010, 151: 365-375.","journal-title":"Br J Haematol"},{"key":"3221_CR37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","volume":"51","author":"M Brecqueville","year":"2012","unstructured":"Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A: Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012, 51: 743-755.","journal-title":"Genes Chromosomes Cancer"},{"key":"3221_CR38","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2011-12-400994","volume":"119","author":"F Damm","year":"2012","unstructured":"Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Curtis CH, Della-Valle V, Couronne L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prebet T, De Botton S, Vey N, Morgan M, Cross JR, Preudhomme C, Birnbaum D, Bernard O, Fontenay M: Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012, 119: 3211-3218.","journal-title":"Blood"},{"key":"3221_CR39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","volume":"44","author":"TA Graubert","year":"2011","unstructured":"Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, Koboldt DC, Larson DE, McLellan MD, Dooling DJ, Abbott RM, Fulton RS, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Grillot M, Baty J, Heath S, Frater JL, Nasim T, Link DC, Tomasson MH, Westervelt P, DiPersio JF, Mardis ER, Ley TJ, Wilson RK, Walter MJ: Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011, 44: 53-57.","journal-title":"Nat Genet"},{"key":"3221_CR40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","volume":"26","author":"TL Lasho","year":"2011","unstructured":"Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP, Pardanani A, Tefferi A: SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2011, 26: 1135-1137.","journal-title":"Leukemia"},{"key":"3221_CR41","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","volume":"119","author":"H Makishima","year":"2012","unstructured":"Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu KS, Jerez A, Przychodzen B, Bupathi M, Guinta K, Afable MG, Sekeres MA, Padgett RA, Tiu RV, Maciejewski JP: Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012, 119: 3203-3210.","journal-title":"Blood"},{"key":"3221_CR42","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","volume":"119","author":"F Thol","year":"2012","unstructured":"Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J, Wlodarski MW, Kolking B, Wichmann M, Gorlich K, Gohring G, Bug G, Ottmann O, Niemeyer CM, Hofmann WK, Schlegelberger B, Ganser A, Heuser M: Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012, 119: 3578-3584.","journal-title":"Blood"},{"key":"3221_CR43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.seminoncol.2011.11.006","volume":"39","author":"AM Jankowska","year":"2012","unstructured":"Jankowska AM, Szpurka H: Mutational determinants of epigenetic instability in myeloid malignancies. Semin Oncol. 2012, 39: 80-96.","journal-title":"Semin Oncol"},{"key":"3221_CR44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/leu.2011.296","volume":"26","author":"C Haferlach","year":"2011","unstructured":"Haferlach C, Grossmann V, Kohlmann A, Schindela S, Kern W, Schnittger S, Haferlach T: Deletion of the tumor-suppressor gene NF1 occurs in 5\u2009% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases. Leukemia. 2011, 26: 834-839.","journal-title":"Leukemia"},{"key":"3221_CR45","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-09-2639","volume":"16","author":"B Parkin","year":"2010","unstructured":"Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D, Purkayastha A, Dressel A, Karp J, Bockenstedt P, Al-Zoubi A, Talpaz M, Kujawski L, Liu Y, Shedden K, Shakhan S, Li C, Erba H, Malek SN: NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res. 2010, 16: 4135-4147.","journal-title":"Clin Cancer Res"},{"key":"3221_CR46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-8-299","volume":"8","author":"V Gelsi-Boyer","year":"2008","unstructured":"Gelsi-Boyer V, Trouplin V, Ad\u00e9laide J, Aceto N, Remy V, Pinson S, Houdayer C, Arnoulet C, Sainty D, Bentires-Alj M, Olschwang S, Vey N, Mozziconacci MJ, Birnbaum D, Chaffanet M: Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008, 8: 299-314.","journal-title":"BMC Cancer"},{"key":"3221_CR47","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/leu.2011.19","volume":"25","author":"PA Greif","year":"2011","unstructured":"Greif PA, Eck SH, Konstandin NP, Benet-Pages A, Ksienzyk B, Dufour A, Vetter AT, Popp HD, Lorenz-Depiereux B, Meitinger T, Bohlander SK, Strom TM: Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia. 2011, 25: 821-827.","journal-title":"Leukemia"},{"key":"3221_CR48","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/leu.2010.135","volume":"24","author":"J Ad\u00e9laide","year":"2010","unstructured":"Ad\u00e9laide J, Gelsi-Boyer V, Rocquain J, Carbuccia N, Birnbaum DJ, Finetti P, Bertucci F, Mozziconacci MJ, Vey N, Birnbaum D, Chaffanet M: Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. Leukemia. 2010, 24: 1539-1541.","journal-title":"Leukemia"},{"key":"3221_CR49","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","volume":"113","author":"FH Grand","year":"2009","unstructured":"Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, Kreil S, Jones A, Score J, Metzgeroth G, Oscier D, Hall A, Brandts C, Serve H, Reiter A, Chase AJ, Cross NC: Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009, 113: 6182-6192.","journal-title":"Blood"},{"key":"3221_CR50","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1200\/JCO.2009.23.7503","volume":"27","author":"H Makishima","year":"2009","unstructured":"Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP: Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009, 27: 6109-6116.","journal-title":"J Clin Oncol"},{"key":"3221_CR51","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","volume":"119","author":"J Score","year":"2011","unstructured":"Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, Zoi K, Ernst T, Stegelmann F, Dohner K, Chase A, Cross NC: Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms. Blood. 2011, 119: 1208-1213.","journal-title":"Blood"},{"key":"3221_CR52","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/gcc.21918","volume":"51","author":"C Haferlach","year":"2012","unstructured":"Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M, Kern W, Haferlach T: ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012, 51: 328-337.","journal-title":"Genes Chromosomes Cancer"},{"key":"3221_CR53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4149\/neo_2012_022","volume":"59","author":"H Cechova","year":"2012","unstructured":"Cechova H, Lassuthova P, Novakova L, Belickova M, Stemberkova R, Jencik J, Stankova M, Hrabakova P, Pegova K, Zizkova H, Cermak J: Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia. Neoplasma. 2012, 59: 168-174.","journal-title":"Neoplasma"},{"key":"3221_CR54","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1172\/JCI45213","volume":"121","author":"R Aucagne","year":"2011","unstructured":"Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, Bataille A, Martin L, Yan KP, Fenaux P, Losson R, Solary E, Bastie JN, Delva L: Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest. 2011, 121: 2361-2370.","journal-title":"J Clin Invest"},{"key":"3221_CR55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm1512","volume":"13","author":"TX Liu","year":"2007","unstructured":"Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT: Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007, 13: 78-83.","journal-title":"Nat Med"},{"key":"3221_CR56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2005.05590.x","volume":"130","author":"K Brakensiek","year":"2005","unstructured":"Brakensiek K, Langer F, Schlegelberger B, Kreipe H, Lehmann U: Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol. 2005, 130: 209-217.","journal-title":"Br J Haematol"},{"key":"3221_CR57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.seminoncol.2011.11.003","volume":"39","author":"MA McDevitt","year":"2012","unstructured":"McDevitt MA: Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. Semin Oncol. 2012, 39: 109-122.","journal-title":"Semin Oncol"},{"key":"3221_CR58","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011, 364: 2496-2506.","journal-title":"N Engl J Med"},{"key":"3221_CR59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","volume":"456","author":"TJ Ley","year":"2008","unstructured":"Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008, 456: 66-72.","journal-title":"Nature"},{"key":"3221_CR60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","volume":"118","author":"T Klampfl","year":"2011","unstructured":"Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, Olcaydu D, Passamonti F, Rumi E, Pietra D, Jager R, Pieri L, Guglielmelli P, Iacobucci I, Martinelli G, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R: Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011, 118: 167-176.","journal-title":"Blood"},{"key":"3221_CR61","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2010.247","volume":"25","author":"P Van Vlierberghe","year":"2011","unstructured":"Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR, Fernandez HF, Tallman MS, Paietta E, Melnick A, Vandenberghe P, Speleman F, Aifantis I, Cools J, Levine R, Ferrando A: PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011, 25: 130-134.","journal-title":"Leukemia"},{"key":"3221_CR62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/leu.2011.200","volume":"26","author":"F Damm","year":"2012","unstructured":"Damm F, Bunke T, Thol F, Markus B, Wagner K, Gohring G, Schlegelberger B, Heil G, Reuter CW, Pullmann K, Schlenk RF, Dohner K, Heuser M, Krauter J, Dohner H, Ganser A, Morgan MA: Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. Leukemia. 2012, 26: 289-295.","journal-title":"Leukemia"},{"key":"3221_CR63","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ajh.21798","volume":"85","author":"J Rocquain","year":"2010","unstructured":"Rocquain J, Gelsi-Boyer V, Ad\u00e9laide J, Murati A, Carbuccia N, Vey N, Birnbaum D, Mozziconacci MJ, Chaffanet M: Alteration of cohesin genes in myeloid diseases. Am J Hematol. 2010, 85: 717-719.","journal-title":"Am J Hematol"},{"key":"3221_CR64","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.febslet.2011.03.068","volume":"585","author":"N Cheung","year":"2011","unstructured":"Cheung N, So CW: Transcriptional and epigenetic networks in haematological malignancy. FEBS Lett. 2011, 585: 2100-2111.","journal-title":"FEBS Lett"},{"key":"3221_CR65","first-page":"197","volume":"67","author":"AH Peters","year":"2011","unstructured":"Peters AH, Schwaller J: Epigenetic mechanisms in acute myeloid leukemia. Prog Drug Res. 2011, 67: 197-219.","journal-title":"Prog Drug Res"},{"key":"3221_CR66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","volume":"463","author":"GL Dalgliesh","year":"2010","unstructured":"Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010, 463: 360-363.","journal-title":"Nature"},{"key":"3221_CR67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","volume":"469","author":"I Varela","year":"2011","unstructured":"Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA: Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011, 469: 539-542.","journal-title":"Nature"},{"key":"3221_CR68","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010, 18: 553-567.","journal-title":"Cancer Cell"},{"key":"3221_CR69","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nature09132","volume":"465","author":"L Dang","year":"2010","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB: Vander Heiden MG, Su SM: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010, 465: 966-","journal-title":"Nature"},{"key":"3221_CR70","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010, 17: 225-234.","journal-title":"Cancer Cell"},{"key":"3221_CR71","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009, 324: 930-935.","journal-title":"Science"},{"key":"3221_CR72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.stem.2011.08.007","volume":"9","author":"L Cimmino","year":"2011","unstructured":"Cimmino L, Abdel-Wahab O, Levine RL, Aifantis I: TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell. 2011, 9: 193-204.","journal-title":"Cell Stem Cell"},{"key":"3221_CR73","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1126\/science.1210597","volume":"233","author":"S Ito","year":"2011","unstructured":"Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y: Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine. Science. 2011, 233: 1300-1303.","journal-title":"Science"},{"key":"3221_CR74","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature10066","volume":"473","author":"K Williams","year":"2011","unstructured":"Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J, Helin K: TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature. 2011, 473: 343-348.","journal-title":"Nature"},{"key":"3221_CR75","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nature04433","volume":"439","author":"Y Tsukada","year":"2006","unstructured":"Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y: Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006, 439: 811-816.","journal-title":"Nature"},{"key":"3221_CR76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer SD, Melnick A, Godley LA, Aifantis I, Levine RL: Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011, 20: 11-24.","journal-title":"Cancer Cell"},{"key":"3221_CR77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C, Couronne L, Della VV, Lopez CK, Plo I, Wagner-Ballon O, Do CM, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA: TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. Cancer Cell. 2011, 20: 25-38.","journal-title":"Cancer Cell"},{"key":"3221_CR78","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vire","year":"2006","unstructured":"Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van EA, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di CL: de LY, Fuks F: The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006, 439: 871-874.","journal-title":"Nature"},{"key":"3221_CR79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","volume":"44","author":"GA Challen","year":"2012","unstructured":"Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, Liang S, Lu Y, Darlington GJ, Meissner A, Issa JP, Godley LA, Li W, Goodell MA: Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012, 44: 23-31.","journal-title":"Nat Genet"},{"key":"3221_CR80","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nature10008","volume":"473","author":"G Ficz","year":"2011","unstructured":"Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, Hore TA, Marques CJ, Andrews S, Reik W: Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature. 2011, 473: 398-402.","journal-title":"Nature"},{"key":"3221_CR81","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature09934","volume":"473","author":"H Wu","year":"2011","unstructured":"Wu H, D'Alessio AC, Ito S, Xia K, Wang Z, Cui K, Zhao K, Sun YE, Zhang Y: Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature. 2011, 473: 389-393.","journal-title":"Nature"},{"key":"3221_CR82","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1128\/MCB.00204-08","volume":"28","author":"T Li","year":"2008","unstructured":"Li T, Hu JF, Qiu X, Ling J, Chen H, Wang S, Hou A, Vu TH, Hoffman AR: CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol. 2008, 28: 6473-6482.","journal-title":"Mol Cell Biol"},{"key":"3221_CR83","first-page":"405","volume":"118","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab O, Adli M, Saunders L, Gao J, Shih A, Pandey S, Jaffe J, Zhao X, Perna F, Caroll M, Melnick A, Nimer SD, Aifantis I, Bernstein B, Levine R: ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression. ASH Annual Meeting Abstracts. 2011, 118: 405-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"3221_CR84","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrg2932","volume":"12","author":"C Beisel","year":"2011","unstructured":"Beisel C, Paro R: Silencing chromatin: comparing modes and mechanisms. Nat Rev Genet. 2011, 12: 123-135.","journal-title":"Nat Rev Genet"},{"key":"3221_CR85","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","volume":"18","author":"P Ntziachristos","year":"2012","unstructured":"Ntziachristos P, Tsirigos A, Vlierberghe PV, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D: da RV, Tang Z, Siegle J, Asp P, Hadler M, Rigo I, Keersmaecker KD, Patel J, Huynh T, Utro F, Poglio S, Samon JB, Paietta E, Racevskis J, Rowe JM, Rabadan R, Levine RL, Brown S, Pflumio F, Dominguez M, Ferrando A, Aifantis I: Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012, 18: 298-303.","journal-title":"Nat Med"},{"key":"3221_CR86","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.20111709","volume":"209","author":"H Oguro","year":"2012","unstructured":"Oguro H, Yuan J, Tanaka S, Miyagi S, Mochizuki-Kashio M, Ichikawa H, Yamazaki S, Koseki H, Nakauchi H, Iwama A: Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J Exp Med. 2012, 209: 445-454.","journal-title":"J Exp Med"},{"key":"3221_CR87","first-page":"in press","volume":"in press","author":"M Brecqueville","year":"2012","unstructured":"Brecqueville M, Ad\u00e9laide J, Bertucci F, Finetti P, Chaffanet M, Birnbaum D, Murati A: Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms. Cell Cycle. 2012, in press: in press-in press","journal-title":"Cell Cycle"},{"key":"3221_CR88","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrm2763","volume":"10","author":"JA Simon","year":"2009","unstructured":"Simon JA, Kingston RE: Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol. 2009, 10: 697-708.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3221_CR89","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","volume":"331","author":"Y Jiao","year":"2011","unstructured":"Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA: Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N: DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011, 331: 1199-1203.","journal-title":"Science"},{"key":"3221_CR90","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jager N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Fruhwald MC, Roggendorf W, Kramm C, Durken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G: von DA, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012, 482: 226-231.","journal-title":"Nature"},{"key":"3221_CR91","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/path.2800","volume":"223","author":"AH Berger","year":"2011","unstructured":"Berger AH, Pandolfi PP: Haplo-insufficiency: a driving force in cancer. J Pathol. 2011, 223: 137-146.","journal-title":"J Pathol"},{"key":"3221_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2009.157","volume":"24","author":"C Acquaviva","year":"2010","unstructured":"Acquaviva C, Gelsi-Boyer V, Birnbaum D: Myelodysplastic syndromes: lost between two states?. Leukemia. 2010, 24: 1-5.","journal-title":"Leukemia"},{"key":"3221_CR93","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1101\/gad.1284605","volume":"19","author":"K Isono","year":"2005","unstructured":"Isono K, Mizutani-Koseki Y, Komori T, Schmidt-Zachmann MS, Koseki H: Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. Genes Dev. 2005, 19: 536-541.","journal-title":"Genes Dev"},{"key":"3221_CR94","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1184208","volume":"327","author":"RF Luco","year":"2010","unstructured":"Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T: Regulation of alternative splicing by histone modifications. Science. 2010, 327: 996-1000.","journal-title":"Science"},{"key":"3221_CR95","first-page":"1841","volume":"22","author":"R Kralovics","year":"2008","unstructured":"Kralovics R: Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008, 22: 1841-1848.","journal-title":"Genetic complexity of myeloproliferative neoplasms. Leukemia"},{"key":"3221_CR96","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","volume":"24","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A: LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010, 24: 1713-1718.","journal-title":"Leukemia"},{"key":"3221_CR97","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006, 108: 3472-3476.","journal-title":"Blood"},{"key":"3221_CR98","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3324\/haematol.13187","volume":"93","author":"S Abbas","year":"2008","unstructured":"Abbas S, Rotmans G, Lowenberg B, Valk PJ: Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica. 2008, 93: 1595-1597.","journal-title":"Haematologica"},{"key":"3221_CR99","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/leu.2009.218","volume":"24","author":"N Carbuccia","year":"2010","unstructured":"Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Ad\u00e9laide J, Olschwang S, Xerri L, Vey N, Chaffanet M, Birnbaum D, Mozziconacci MJ: Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia. 2010, 24: 469-473.","journal-title":"Leukemia"},{"key":"3221_CR100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/1471-2407-10-401","volume":"10","author":"J Rocquain","year":"2010","unstructured":"Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N, Birnbaum D, Gelsi-Boyer V, Mozziconacci MJ: Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010, 10: 401-405.","journal-title":"BMC Cancer"},{"key":"3221_CR101","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1182\/blood-2011-03-343988","volume":"118","author":"Y Shen","year":"2011","unstructured":"Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, Gu ZH, Wang YY, Chen B, Jiang CL, Yan H, Chen FF, Chen HM, Chen Z, Jin J, Chen SJ: Gene mutation patterns and their prognostic impact in a cohort of 1,185 patients with acute myeloid leukemia. Blood. 2011, 118: 5593-5603.","journal-title":"Blood"},{"key":"3221_CR102","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/leu.2008.228","volume":"23","author":"F Bernard","year":"2009","unstructured":"Bernard F, Gelsi-Boyer V, Murati A, Giraudier S, Trouplin V, Ad\u00e9laide J, Rey J, Olschwang S, Vainchenker W, Chaffanet M, Vey N, Mozziconacci MJ, Birnbaum D: Alterations of NFIA in chronic malignant myeloid diseases. Leukemia. 2009, 23: 583-585.","journal-title":"Leukemia"},{"key":"3221_CR103","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMc1108665","volume":"365","author":"F Damm","year":"2011","unstructured":"Damm F, Fontenay M, Bernard OA: Point mutations in myelodysplastic syndromes. N Engl J Med. 2011, 365: 1154-1155.","journal-title":"N Engl J Med"},{"key":"3221_CR104","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-0-387-69259-3_11","volume":"145","author":"JM Fortier","year":"2010","unstructured":"Fortier JM, Graubert TA: Murine models of human acute myeloid leukemia. Cancer Treat Res. 2010, 145: 183-196.","journal-title":"Cancer Treat Res"},{"key":"3221_CR105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.leu.2403670","volume":"19","author":"E McCormack","year":"2005","unstructured":"McCormack E, Bruserud O, Gjertsen BT: Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia. 2005, 19: 687-706.","journal-title":"Leukemia"},{"key":"3221_CR106","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3324\/haematol.2011.042846","volume":"96","author":"E Pronier","year":"2011","unstructured":"Pronier E, Quivoron C, Bernard OA, Villeval JL: JAK2V(1)F\/TET2 mutations: does the order matter?. Haematologica. 2011, 96: 638-640.","journal-title":"Haematologica"},{"key":"3221_CR107","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","volume":"366","author":"MJ Walter","year":"2012","unstructured":"Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, Larson DE, McLellan MD, Dooling D, Abbott R, Fulton R, Magrini V, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Fan X, Grillot M, Witowski S, Heath S, Frater JL, Eades W, Tomasson M, Westervelt P, DiPersio JF, Link DC, Mardis ER, Ley TJ, Wilson RK, Graubert TA: Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012, 366: 1090-1098.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3221_CR108","doi-asserted-by":"crossref","first-page":"11842","DOI":"10.1073\/pnas.2034201100","volume":"100","author":"E Passegue","year":"2003","unstructured":"Passegue E, Jamieson CH, Ailles LE, Weissman IL: Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci U S A. 2003, 100 (Suppl 1): 11842-11849.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3221_CR109","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood-2009-03-209916","volume":"114","author":"JR Lambert","year":"2009","unstructured":"Lambert JR, Everington T, Linch DC, Gale RE: In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood. 2009, 114: 3018-3023.","journal-title":"Blood"},{"key":"3221_CR110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/shem.2002.36921","volume":"39","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG: Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002, 39: 6-11.","journal-title":"Semin Hematol"},{"key":"3221_CR111","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","volume":"461","author":"MA Dawson","year":"2009","unstructured":"Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR, Kouzarides T: JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009, 461: 819-822.","journal-title":"Nature"},{"key":"3221_CR112","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","volume":"29","author":"R Bejar","year":"2011","unstructured":"Bejar R, Levine R, Ebert BL: Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011, 29: 504-515.","journal-title":"J Clin Oncol"},{"key":"3221_CR113","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","volume":"117","author":"H Makishima","year":"2011","unstructured":"Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, Paquette R, Maciejewski JP: CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011, 117: e198-e206.","journal-title":"Blood"},{"key":"3221_CR114","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2011.139","volume":"25","author":"C Roche-Lestienne","year":"2011","unstructured":"Roche-Lestienne C, Marceau A, Labis E, Nibourel O, Coiteux V, Guilhot J, Legros L, Nicolini F, Rousselot P, Gardembas M, Helevaut N, Frimat C, Mahon FX, Guilhot F, Preudhomme C: Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia. 2011, 25: 1661-1664.","journal-title":"Leukemia"},{"key":"3221_CR115","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC, De VJ, Hernandez JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foa R: Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010, 28: 2529-2537.","journal-title":"J Clin Oncol"},{"key":"3221_CR116","doi-asserted-by":"crossref","first-page":"9381","DOI":"10.1038\/sj.onc.1207910","volume":"23","author":"N Vey","year":"2004","unstructured":"Vey N, Mozziconacci MJ, Groulet-Martinec A, Debono S, Finetti P, Carbuccia N, Beillard E, Devilard E, Arnoulet C, Coso D, Sainty D, Xerri L, Stoppa AM, Lafage-Pochitaloff M, Nguyen C, Houlgatte R, Blaise D, Maraninchi D, Birg F, Birnbaum D, Bertucci F: Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene. 2004, 23: 9381-9391.","journal-title":"Oncogene"},{"key":"3221_CR117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","volume":"17","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J: van PW, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Lowenberg B, Delwel R, Melnick A: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010, 17: 13-27.","journal-title":"Cancer Cell"},{"key":"3221_CR118","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2010.65","volume":"24","author":"J Boultwood","year":"2010","unstructured":"Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, Pellagatti A, Wang L, Clark RE, Wainscoat JS: High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia. 2010, 24: 1139-1145.","journal-title":"Leukemia"},{"key":"3221_CR119","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2010-05-283291","volume":"116","author":"WC Chou","year":"2010","unstructured":"Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF: Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010, 116: 4086-4094.","journal-title":"Blood"},{"key":"3221_CR120","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.2010.33.4938","volume":"29","author":"F Thol","year":"2011","unstructured":"Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Gohring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A: Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2011, 29: 2499-2506.","journal-title":"J Clin Oncol"},{"key":"3221_CR121","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","volume":"96","author":"BL Stein","year":"2011","unstructured":"Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR: Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011, 96: 1462-1469.","journal-title":"Haematologica"},{"key":"3221_CR122","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2009-04-215814","volume":"114","author":"O Kosmider","year":"2009","unstructured":"Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguie F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De MV, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M: TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009, 114: 3285-3291.","journal-title":"Blood"},{"key":"3221_CR123","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","volume":"29","author":"KH Metzeler","year":"2011","unstructured":"Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011, 29: 1373-1381.","journal-title":"J Clin Oncol"},{"key":"3221_CR124","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2009-07-234484","volume":"116","author":"O Nibourel","year":"2010","unstructured":"Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C: Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010, 116: 1132-1135.","journal-title":"Blood"},{"key":"3221_CR125","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van VP, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012, 366: 1079-1089.","journal-title":"N Engl J Med"},{"key":"3221_CR126","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012, 366: 787-798.","journal-title":"N Engl J Med"},{"key":"3221_CR127","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOH.0b013e3283439964","volume":"18","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Tefferi A: Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol. 2011, 18: 105-110.","journal-title":"Curr Opin Hematol"},{"key":"3221_CR128","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH: Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012, 366: 799-807.","journal-title":"N Engl J Med"},{"key":"3221_CR129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1126\/science.1201662","volume":"333","author":"L Wang","year":"2011","unstructured":"Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, Jiang Y, Cole PA, Zhang J, Melnick A, Roeder RG, Nimer SD: The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation. Science. 2011, 333: 765-769.","journal-title":"Science"},{"key":"3221_CR130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","volume":"25","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Kosmider O, Cluzeau T, Mansat-De MV, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Ades L, Fenaux P, Fontenay M: Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011, 25: 1147-1152.","journal-title":"Leukemia"},{"key":"3221_CR131","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/hon.976","volume":"29","author":"DA Pollyea","year":"2010","unstructured":"Pollyea DA, Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS: Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematol Oncol. 2010, 29: 157-160.","journal-title":"Hematol Oncol"},{"key":"3221_CR132","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1111\/j.1742-4658.2011.08387.x","volume":"278","author":"A Yokoi","year":"2011","unstructured":"Yokoi A, Kotake Y, Takahashi K, Kadowaki T, Matsumoto Y, Minoshima Y, Sugi NH, Sagane K, Hamaguchi M, Iwata M, Mizui Y: Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J. 2011, 278: 4870-4880.","journal-title":"FEBS J"},{"key":"3221_CR133","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nm.2546","volume":"18","author":"R Amson","year":"2012","unstructured":"Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, Tosoni D, Colaluca I, Viale G, Rodrigues-Ferreira S, Wynendaele J, Chaloin O, Hoebeke J, Marine JC, Di Fiore PP, Telerman A: Reciprocal repression between P53 and TCTP. Nat Med. 2012, 18: 91-99.","journal-title":"Nat Med"},{"key":"3221_CR134","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","volume":"8","author":"VJ Bykov","year":"2002","unstructured":"Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002, 8: 282-288.","journal-title":"Nat Med"},{"key":"3221_CR135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","volume":"25","author":"S Roychowdhury","year":"2011","unstructured":"Roychowdhury S, Talpaz M: Managing resistance in chronic myeloid leukemia. Blood Rev. 2011, 25: 279-290.","journal-title":"Blood Rev"},{"key":"3221_CR136","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrd3374","volume":"10","author":"DA Chan","year":"2011","unstructured":"Chan DA, Giaccia AJ: Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov. 2011, 10: 351-364.","journal-title":"Nat Rev Drug Discov"},{"key":"3221_CR137","first-page":"1189","volume":"6","author":"F Eisinger","year":"1999","unstructured":"Eisinger F, Sobol H, Birnbaum D: Hypothesis: more mutations to cure cancer?. Oncol Rep. 1999, 6: 1189-1190.","journal-title":"Oncol Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-304\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T16:57:32Z","timestamp":1630601852000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,23]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3221"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-304","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,23]]},"assertion":[{"value":"5 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"304"}}